4SCAR-CD44v6 T Cell Therapy
/ SZGIMI
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 11, 2020
4SCAR-CD44v6 T Cell Therapy Targeting Cancer
(clinicaltrials.gov)
- P1/2; N=100; Recruiting; Sponsor: Shenzhen Geno-Immune Medical Institute
Clinical • New P1/2 trial • Oncology
1 to 1
Of
1
Go to page
1